MS, APRN, FNP,PHILADELPHIA — Antimicrobial resistance to all Streptococcus pneumoniae has been estimated at 30% to 40% for products such as erythromycin and azithromycin, and rising fluoroquinolone resistance has made treating bacterial cases more difficult, according to a recent presentation at the annual meeting of the American Association of Nurse Practitioners.

“This is frightening because in my world, and in [many practitioner’s] worlds, this is the best class of antibiotic we have from a spectrum perspective,” Wendy L. Wright, MS, APRN, FNP, said in her presentation. “They have side effects, but if I need to treat particular infections, this is the best drug we have for many people on an outpatient basis.”